Comparison of Aβ levels in the brain of familial and sporadic Alzheimer's disease

Neurochemistry International

Volumn 55, Issue 4, 2009, Pages 243-252

  Hellstrom Lindahl E ^a   Viitanen, M ^a,b   Marutle, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Alzheimer's disease; Amyloid peptide; APP mutation; Cortex; Familial AD; Postmortem human brain; Presenilin mutation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PRESENILIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FRONTAL CORTEX; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; OCCIPITAL CORTEX; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TEMPORAL CORTEX; BRAIN; COMPARATIVE STUDY; FAMILY HEALTH; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; SENILE PLAQUE;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CEREBRAL CORTEX; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDE FRAGMENTS; PRESENILIN-1; SENILE PLAQUES;

EID: 67349175242     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.03.007     Document Type: Article

References (67)

1. Ancolio K., Marambaud P., Dauch P., and Checler F. α-Secretase-derived product of β-amyloid precursor protein is decreased by presenilin 1 mutations linked to familial Alzheimer's disease. J. Neurochem. 69 (1997) 2494-2499
2. Arrigada P.V., Growdon J.H., Hedely W.E., and Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 (1992) 631-639
3. Axelman K., Basun H., Winblad B., and Lannfelt L. A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation: a clinical and genealogical investigation. Arch. Neurol. 51 (1994) 1193-1197
4. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horré K., Wiltfang J., Esselmann H., and De Strooper B. Presenilin clinical mutations can effect γ-secretase activity by different mechanisms. J. Neurochem. 96 (2006) 732-742
5. 670,671 mutation carriers: implications for late-onset Alzheimer's disease. J. Cell. Mol. Med. 6 (2002) 199-214
6. Bojarski L., Herms J., and Kuznicki J. Calcium dysregulation in Alzheimer's disease. Neurochem. Int. 52 (2008) 621-633
7. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratoitsky T., Prada C.-M., Kim G., Seekens S., Yager D., Slunt H.H., Wang R., Seeger M., Levey A.I., Gandy S.E., Copeland N.G., Jenkins N., Price D.L., Younkin S.G., and Sisodia S.S. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996) 1005-1013
8. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Liberburg I., and Selkoe D.J. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360 (1992) 672-674
9. Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser R., St. George-Hyslop P., and Selkoe D.J. Mutant presenilins of Alzheimer's diease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med. 3 (1997) 67-72
10. Clark R.F., Hutton M., Fuldner R.A., Froelich S., Karran E., Talbot C., Crook R., Lendon C., Prihar G., He C., Korenblat K., Martinez A., Wragg M., Busfield F., Behrens M.I., Myers A., Norton J., Morris J., Mehta N., Pearson C., Lincoln S., Baker M., Duff K., Zehr C., Perez-Tur J., Houlden H., Ruiz A., Ossa J., Lopera F., Arcos M., Madrigal L., Collinge J., Humphreys C., Ashwoth T., Sarner S., Fox N., Harvey R., Kennedy A., Roques P., Cline R.T., Philips C.A., Venter J.C., Forsell L., Axelman K., Lilius L., Johnston J., Cowburn R., Viitanen M., Winblad B., Kosik K., Haltia M., Poyhonen M., Dickson D., Mann D., Neary D., Snowden J., Lantos P., Lannfelt L., Rossor M., Roberts G.W., Adams M.D., Hardy J., and Goate A. The structure of the presenilin 1 (S 182) gene and identification of six novel mutations in early onset AD families. Nat. Genet. 11 (1995) 219-222
11. Crook R., Verkkoniemi A., Perez-Tur J., Mehta N., Baker M., Houlden H., Farrer M., Hutton M., Lincoln S., Hardy J., Gwinn K., Somer M., Paetau A., Kalimo H., Ylikoski R., Pöyhönen M., Kucera S., and Haltia M. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat. Med. 4 (1998) 452-455
12. Deng Y., Tarassishin L., Kallhoff V., Peethumnongsin E., Wu L., Li M.-W., and Zheng H. Deletion of presenilin 1 hydrophilic loop sequence leads to impaired γ-secretase activity and exacerbated amyloid pathology. J. Neurosci. 26 (2006) 3845-3854
13. De Strooper B. Loss-of-function presenilin mutations in Alzheimer disease. EMBO Rep. 8 (2006) 141-146
14. Duering M., Grimm M.O., Grimm H.S., Schröder J., and Hartmann T. Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol. Aging 26 (2005) 785-788
15. Duff K., Eckman C., Zehr C., Yu X., Prada C.M., Perez-Tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., and Younkin S. Increased amyloid-beta 42(43) in brains of mice expressing mutant presenilin 1. Nature 383 (1996) 710-713
16. Engelborghs S., Dermaut B., Goeman J., Saerens J., Marien P., Pickut B.A., Van den B.M., Serneels S., Cruts M., Van Broeckhoven C., and De Deyn P.P. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J. Neurol. Neurosurg. Psychiatry 74 (2003) 1148-1151
17. Evin G., and Weidemann A. Biogenesis and metabolism of Alzheimer's disease Aβ amyloid peptides. Peptides 23 (2002) 1285-1297
18. Funato H., Yoshimura M., Kusui K., Tamaoka A., Ishikawa K., Ohkoshi N., Namekata K., Okeda R., and Ihara Y. Quantitation of amyloid β-protein (Aβ) in the cortex during aging and in Alzheimer's disease. Am. J. Pathol. 152 (1998) 1633-1640
19. Giannakopoulos P., Herrmann F.R., Bussiere T., Bouras C., Kovari E., Perl D.P., Morrison J.H., Gold G., and Hof P.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 (2003) 1495-1500
20. Gómez-Isla T., Growdon W.B., McNamara M.J., Nochlin D., Bird T.D., Arango J.C., Lopera F., Kosik K.S., Lantos P.L., Cairns N.J., and Hyman B.T. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuron loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain 122 (1999) 1709-1719
21. Gravina S.A., Ho L., Eckman C.B., Long K.E., Otvos Jr. L., Younkin L.H., Suzuki N., and Younkin S.G. Amyloid β protein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J. Biol. Chem. 270 (1995) 7013-7016
22. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. 8 (2007) 101-112
23. Haltia M., Viitanen M., Sulkava R., Ala-Hurula V., Poyhonen M., Goldfarb L., Brown P., Levy E., Houlden H., Crook R., Goate A., Clark R., Korenblat K., Pandit S., Keller H.D., Lilius L., Liu L., Axelman K., Forsell L., Winblad B., Lannfelt L., and Hardy J. Chromosome 12-encoded Alzheimer's disease: genetic and clinicopathological description. Ann. Neurol. 36 (1994) 362-367
24. Hellström-Lindahl E., Mousavi M., Ravid R., and Nordberg A. Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients. Neurobiol. Dis. 15 (2004) 351-360
25. Hellström-Lindahl E., Ravid R., and Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with Aβ levels. Neurobiol. Aging 29 (2008) 210-221
26. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St. George-Hyslop P.H., Mirra S.S., and Mori H. Aβ 1-40 but not Aβ 1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748 (1997) 250-252
27. Jarrett J.T., Berger E.P., and Lansbury P.T. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
28. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Hsiao Ashe K., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001) 372-381
29. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D.W., Golde T., and McGowan E. Abeta 40 inhibits amyloid deposition in vivo. J. Neurosci. 27 (2007) 627-633
30. Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., and Van Broeckhoven C. Mean age of onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ 40. Hum. Mutat. 27 (2006) 686-695
31. Lannfelt L., Bogdanovic N., Appelgren H., Axelman K., Lilius L., Hansson G., Schenk D., Hardy J., and Winblad B. Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family. Neurosci. Lett. 168 (1994) 254-256
32. Lee H., Zhu X., Castellani R.J., Nunomuro A., Perry G., and Smith M.A. Amyloid-β in Alzheimer disease: the null versus the alternate hypothesis. J. Pharm. Exp. Ther. 321 (2007) 823-829
33. Lleó A., Berezovska O., Growdon J.H., and Hyman B.T. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am. Geriatr. Psychiatry 12 (2004) 146-156
34. Lippa C.F., Saunders A.M., Smith T.W., Swearer J.M., Drachman D.A., Ghetti B., Nee L., Pulaski-Salo D., Dickson D., Robitaille Y., Bergeron C., Crain B., Benson M.D., Farlow M., Hyman B.T., St George-Hyslop P., Roses A.D., and Pollen D.A. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 46 (1996) 406-412
35. Lue L.-F., Kuo Y.-M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
36. 42(43). Ann. Neurol. 40 (1996) 149-156
37. 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am. J. Pathol. 148 (1996) 1257-1266
38. Mann D.M.A., Iwatsubo T., Pickering-Brown S.M., Owen F., Saido T.C., and Perry R.H. Preferential deposition of amyloid protein (Aβ) in the form of Aβ 40 in Alzheimers's disease is associated with gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221 (1997) 81-84
39. Mann D.M.A., Pickering-Brown S.M., Takeuchi A., Iwatsubo T., and and the members of the Familial Alzheimer's Disease Pathology Study Group. Amyloid angiopathy and variability in amyloid β deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease. Am. J. Pathol. 158 (2001) 2165-2175
40. Marks N., and Berg M.J. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem. Int. 52 (2008) 184-215
41. Marutle A., Warpman U., Bogdanovic N., Lannfelt L., and Nordberg A. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J. Neurochem. 72 (1999) 1161-1169
42. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., and Golde T. Aβ 42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47 (2005) 191-199
43. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of department of health and human services task forces on Alzheimer's disease. Neurology 34 (1984) 939-944
44. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
45. Menédez M. Pathological and clinical heterogeneity of presenilin 1 gene mutations. J. Alzheimers Dis. 6 (2004) 475-482
46. Morishima-Kawashima M., Oshima N., Ogata H., Yamaguchi H., Yoshimura M., Sugihara S., and Ihara Y. Effect of apolipoprotein E allele ε4 on the initial phase of amyloid β-protein accumulation in the human brain. Am. J. Pathol. 157 (2000) 2093-2099
47. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConloge L. High-level neuronal expression of Abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
48. Murayama O., Tomita T., Nihonmatsu N., Murayama M., Sun X., Honda T., Iwatsubo T., and Takashima A. Enhancement of amyloid β 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer's disease. Neurosci. Lett. 2665 (1999) 61-63
49. Pákáski M., and Kálmán J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem. Int. 53 (2008) 103-111
50. Price J.L., and Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45 (1999) 358-368
51. Ray W.J., Ashall F., and Goate A.M. Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease. Mol. Med. Today 4 (1998) 151-157
52. Saganich M.J., Schroeder B.E., Galvan V., Bredesen D., Koo E.H., and Heinemann S.E. Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J. Neurosci. 26 (2006) 13428-13436
53. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkai P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
54. Selkoe D.J. Alzheimer's disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 140 (2004) 627-638
55. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
56. Shankar G.M., Li S., Mehta T.M., Garci-Munoz A., Shepardson N.E., Smith I., Breatt F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., and Selkoe D.J. Amyloid-b protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008) 837-842
57. Shen J., and Kelleher R.J. The presenilin hypothesis of Alzheimer's disease: evidence for loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 403-409
58. Shimojo M., Sahara N., Murayama M., Ichinose H., and Takashima A. Decreased Aβ secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Neurosci. Res. 57 (2007) 446-453
59. Stenh C., Englund H., Lord A., Johansson A.-S., Almeida C.G., Gellerfors P., Greengard P., Gouras G.K., Lannfelt L., and Nilsson L.N.G. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 58 (2005) 147-150
60. 11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 54 (2009) 347-357
61. Takeda K., Araki W., and Tabira T. Enhanced generation of intracellular Aβ42 amyloid peptide by mutation of presenilins PS1 and PS2. Eur. J. Neurosci. 19 (2004) 258-264
62. Tamaoka A., Fraser P.E., Ishii K., Sahara N., Ozawa K., Ikeda M., Saunders A.M., Komatsuzaki Y., Sherrington R., Levesque G., Yu G., Rogaeva E., Shoji S., Nee L.E., Pollen D.A., Hendriks L., Martin J.J., Van Broeckhoven C., Roses A.D., Farrer L.A., St. George-Hyslop P.H., and Mori H. Amyloid-β-protein isoforms in brain of subjects with PS1-linked, βAPP-linked and sporadic Alzheimer disease. Mol. Brain Res. 56 (1998) 178-185
63. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physiological bases of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
64. Thal D.R., Rüb U., Orantes M., and Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58 (2002) 1791-1800
65. Verkkoniemi A., Somer M., Rinne J.O., Myllykangas L., Crook R., Hardy J., Viitanen M., Kalimo H., and Haltia M. Variant Alzheimer's disease with spastic paraparesis: clinical characterization. Neurology 54 (2000) 1103-1109
66. Walsh D.M., and Selkoe D.J. Aβ oligomers-decade of discovery. J. Neurochem. 101 (2007) 1172-1184
67. Wang J., Dickson D.W., Trojanowski J.Q., and Lee V.M.-Y. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 58 (1999) 328-337